Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

URL Brings Gout Drug To Takeda

by Rick Mullin
April 16, 2012 | A version of this story appeared in Volume 90, Issue 16

Takeda Pharmaceuticals has agreed to acquire Philadelphia-based URL Pharmaceuticals for $800 million up front plus unspecified performance-based milestone payments. URL, which had $600 million in sales last year, specializes in gout treatment. Its lead product, Colcrys, had 2011 sales of $430 million. Takeda’s lead gout treatment is Uloric, used to lower blood uric acid levels in adults with gout.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.